You are here

LASER FOR SELECTIVE PHOTOTHERMOATHEROLYSIS

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N/A
Agency Tracking Number: 4969
Amount: $500,000.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 1988
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
530 Boston Post Road
Wayland, MA 01778
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 James C Hsia
 Principal Investigator
 (617) 358-7637
Business Contact
Phone: () -
Research Institution
N/A
Abstract

CARDIOVASCULAR DISEASE IS THE LEADING CAUSE OF DEATHS IN THEUNITED STATES, CLAIMING NEARLY TWICE AS MANY LIVES AS CANCER. LASER ANGIOPLASTY HAS IMMENSE APPEAL, BUT A RELIABLE, PREDICTABLE SYSTEM HAS NOT YET BEEN DEVELOPED. RESEARCHERS HAVE CONDUCTED PRELIMINARY STUDIES TO DEMONSTRA-TE PREFERENTIAL ABSORPTION OF DYE LASER ENERGY BY ANTHERO- MATOUS PLAQUES WITH MINIMAL ABSORPTION BY NORMAL ARTERIAL WALL. CANDELA WILL INVESTIGATE THE OPERATING PARAMETERS OF ENERGY, DENSITY, AND PULSEWIDTH TO FURTHER OPTIMIZE THE THE SELECTIVE ABSORPTION PROCESS IN ARTERIAL PLAQUES. SPECIFICALLY, RESEARCHERS WILL CONDUCT IN VITRO STUDIES OF DYE LASER PLAQUE ABLATION IN THE LONG-PULSE, MILLISECOND, AND SHORT-PULSE SUBMICROSECOND REGIMES. STUDIES WILL MAXI- MIZE PLAQUE ABLATION EFFICIENCY FOR VARIOUS TYPES OF COMMONLY OCCURRING PLAQUE TYPES WHILE MINIMIZING IRREVERSI- BLE DAMAGE TO THE UNDERLYING VASCULAR TISSUE. IF SUCCESSFUL, ANIMAL STUDIES WILL BE UNDERTAKEN TO ESTABLISH THE SAFETY AND EFFICACY OF THE TREATMENT TECHNIQUES IN PHASEII. CANDELA WILL ALSO PURSUE DESIGN AND DEVELOPMENT OF A CLINICAL SYSTEM IN PHASE II.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government